Protein C concentrate (human)
- First approval year
- 2001
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Unknown
- Drug name
- Protein C concentrate (human)
- ceprotin
- Ceprotin
- protein c component of balfaxar
- Protein c component of balfaxar
- ceprotin
- human protein c
- Human protein c
- human protein c concentrate
- Human protein C concentrate
- protein c
- Protein c
- Protein c (coagulation inhibitor)
- Protein c (homo sapiens)
- protein c coagulation inhibitor
- Protein C concentrate
- Protein c concentrate (human)
- protein c concentrate human
- protein c homo sapiens
- protein c human
- Protein c human
- protexel
- Protexel
- ATC classification codes
- B01AD12
Sources for recorded values
- ChEMBL ID
- CHEMBL5315087
- 8834
- 723868
- Patents
- 0
- Designations
- 1
- Earliest recorded loss of exclusivity
- 30 Mar 2014
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
Mechanisms of action
- Mechanism
- Vitamin K-dependent protein C exogenous protein
- Action type
- EXOGENOUS_PROTEIN
- Target
- Vitamin K-dependent protein C
- Protein identifier
- P04070
Open Targets mechanisms
- Mechanism
- Vitamin K-dependent protein C exogenous protein
- Action type
- EXOGENOUS PROTEIN
- Target
- Vitamin K-dependent protein C
- Condition
- Venous Thrombosis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003907
- Subject identifier
- D020246
- Condition
- Protein C Deficiency
- Highest recorded phase
- 4
- Condition identifier
- EFO:0009316
- Subject identifier
- D020151
- Condition
- Purpura Fulminans
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001913
- Subject identifier
- D055665
- Condition
- Thrombosis
- Highest recorded phase
- 4
- Condition identifier
- HP:0004419
- Subject identifier
- D013927
- Condition identifier
- EFO_0004286
- Condition identifier
- EFO_0009315
- Condition identifier
- EFO_0009316
- Condition identifier
- EFO_0009316
- Highest recorded phase
- 4
- Condition identifier
- EFO_1001913
- Condition identifier
- EFO_1001913
- Highest recorded phase
- 4
- Condition identifier
- HP_0004419
- Condition identifier
- HP_0004419
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0002305
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005399
- Highest recorded phase
- 4
- Event
- amputation
- Reports
- 3
- Reporting signal score
- 18.1426
- Event
- leg amputation
- Reports
- 2
- Reporting signal score
- 9.47018
- Event
- purpura fulminans
- Reports
- 2
- Reporting signal score
- 13.9902
- Event
- vascular device infection
- Reports
- 3
- Reporting signal score
- 15.6678
- Dose
- 100-120 IU/kg, 60-80 IU/kg, 45-60 IU/kg
- Route
- Intravenous
- How often
- Every 6 hours, every 12 hours, until desired anticoagulation is achieved, and then maintained
Conditions of use
- Administer at a maximum rate of 2 mL per minute, or 0.2 mL/kg/min in children under 10kg
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (486)
- A Clinical Study of Intravenous Immunoglobulin
- A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy
- A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers
- A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers.
- A Controlled Study to Evaluate the Safety and Immunogenicity of StreptAnova™ in Healthy Adults
- A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion
- A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors
- A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection
- A Novel Therapeutic Treatment of Pyoderma Gangrenosum
- A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency
- A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
- A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
- A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
- A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
- A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children
- A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
- A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
- A Phase Ⅲ Clinical Study of SNA02-48 Injection
- A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
- A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
Approved for (3)
- Hereditary thrombophilia due to congenital protein C deficiency
- Purpura fulminans
- Thrombotic disease
Other linked conditions (2)
- Thrombophilia
- Venous thromboembolism
Targets (1)
- PROC Vitamin K-dependent protein C exogenous protein